Collaboration between Ayoxxa and Singapore Eye Research Institute Announced

Ayoxxa, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. Ayoxxa and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools.

“We are pleased to start this collaboration with such a prestigious research institute like SERI,” said Michael Rasche, Corporate Vice President Global Commercial Operations of Ayoxxa Biosystems GmbH. “By gaining access to very low-volume samples from the eye we can prove the benefits of our new protein multiplex technology beyond the research segment in clinical settings. We want to closely work with SERI in the ophthalmology space and potentially use our technology as new diagnostic application in the treatment of age-related macular degeneration (AMD).”

“SERI has had a long and broad history of working with large and mid-size pharmaceutical and ophthalmic companies, and we are now keen to expand our collaboration scope to working with promising start-up companies from around the world, be it biotech, diagnostics or device companies, with our goal of positioning Singapore as one of the world hubs for innovative technology development in ophthalmology,” said Professor Tin Aung, Executive Director of SERI. ”The partnership with Ayoxxa can potentially enable the co-development of a range of ophthalmic diagnostic tools, beginning with AMD. Having a validated diagnostic platform can potentially help better assess patients and more objectively steer their treatment. It can also potentially assist in the development of new treatments.”

Research teams led by Dr Dieter Trau, Associate Professor at the Department of Biomedical Engineering of the National University of Singapore and Co-founder of Ayoxxa, and Professor Wong Tien Yin, one of world’s top eye researchers and Medical Director at the Singapore National Eye Centre (SNEC), will closely work together during this pilot study.